Cost-effectiveness analysis of biologic sequential treatments for moderate-to-severe psoriasis: A Malaysian healthcare system perspective
Adding biosimilar to the current treatment sequence could achieve cost savings ranging from 4.3% to 10.8% without significant loss of effectiveness. Given the significant impact of comorbidities and the resulting decline in quality of life among individuals with psoriasis, it may be justifiable to establish a threshold of up to US$184,000 per quality-adjusted life year (QALY) for the provision of therapies in the context of Malaysia.
Authors
- Amirah binti Azzeri (ORCID: https://orcid.org/0000-0001-6261-1307)
- Nor Azmaniza Azizam (ORCID: https://orcid.org/0000-0003-1613-4313)
- Wei Chern Ang (ORCID: https://orcid.org/0000-0002-6599-3301)
- Mofakhar Hussain (ORCID: https://orcid.org/0000-0003-0096-5032)
- Jacob Smith (ORCID: https://orcid.org/0000-0001-7179-9567)
Institutions
- Ministry of Health (MY)
- Universiti Sains Islam Malaysia (MY)
- University of Toronto (CA)
- Universiti Teknologi MARA (MY)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-09-06
- DOI
- https://doi.org/10.1371/journal.pone.0307234
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- University of Toronto
- Hospital for Sick Children